Unknown PHASE3 INTERVENTIONAL 2-arm NCT06126965

Phase III Study of KX-826 With Adult Male Patients With AGA

A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of KX-826 for Topical Use in Chinese Adult Male Patients With Androgenetic Alopecia (AGA)

Sponsor: Suzhou Kintor Pharmaceutical Inc,

Conditions Androgenetic Alopecia

Interventions KX-826-（5%） BID Placebo

Updated 5 times since 2023 Last updated: Apr 1, 2024 Started: Dec 29, 2021 Primary completion: May 31, 2024 Completion: May 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06126965, this PHASE3 trial focuses on Androgenetic Alopecia and remains ongoing. Sponsored by Suzhou Kintor Pharmaceutical Inc,, it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE3

Status: Active Not Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3
Dec 2023 — May 2024 [monthly]

Active Not Recruiting PHASE3

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Suzhou Kintor Pharmaceutical Inc,
Suzhou Koshine Biomedica, Inc.

Data source: Suzhou Kintor Pharmaceutical Inc,

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changsha, China , Chengdou, China , Chongqing, China , Guangzhou, China , Hangzhou, China , Hefei, China , Shanghai, China , Shenyang, China , Shenzhen, China and 6 more locations